Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02926573 · ClinicalTrials.gov registry record · Phase 4

Perioperative Gabapentin Use In Head And Neck Mucosal Surgery Patients

A Phase 4 study of Head and Neck Cancer and Postoperative Pain, sponsored by Washington University School of Medicine.

Completed
Registry status
Phase 4
Development phase
123
Enrollment target
1
Study location

NCT02926573: Completed Phase 4 study of Head and Neck Cancer and Postoperative Pain, sponsored by Washington University School of Medicine.

NCT02926573 is a Phase 4 study of Head and Neck Cancer and Postoperative Pain that has completed, run by Washington University School of Medicine. The registered enrollment target is 123 participants, below the 260-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (53% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02926573, a Phase 4 study of Head and Neck Cancer and Postoperative Pain, has completed, sponsored by Washington University School of Medicine.

COMPLETED
Registry status
Phase 4
Development phase
123 participants
Enrollment target
1
Study location

Study Summary

Patient satisfaction with healthcare is increasingly being utilized as a metric to reflect provider and hospital quality of care. Furthermore, at the core of a healthcare team and healthcare system is the desire to provide patients with the best possible care in order to achieve the best possible outcomes. Providers have the duty to identify areas of needed improvement within the domains of treatment. An area of need that is ubiquitous within medicine is pain control; in this case acute postoperative pain control is the targeted condition. Studies have already shown that better control of acute postoperative pain leads to shortened hospital stays, reduced hospital costs and patient morbidity, improved patient satisfaction and a reduced likelihood of developing chronic pain. Research within the field of pain management has definitively revealed that a combination of different medication regimens can control acute postoperative pain better than narcotics alone. In particular, the medication gabapentin has been shown to improve acute postop pain in many kinds of surgical settings, and it is a safe medication with arguably fewer side effects than narcotics. The investigators know that certain groups of post surgical otolaryngology patients can be at risk for high levels of postoperative pain. Given all of this information, physicians have a responsibility to utilize medications such as gabapentin to do a better job of controlling patient's pain. This investigation is a quality improvement project designed to elucidate the benefits of gabapentin in pain management in patients undergoing surgery of the head and neck mucosal surfaces. It will provide much needed data in an understudied population and ultimately will improve the practice of pain management, patient satisfaction and quality of care delivered in the Barnes otolaryngology department.

Primary Outcome

Total amount of narcotic use in morphine equivalents will be divided by the total hours of inpatient hospitalization, multiplied by 24 hours, to obtain the daily narcotic consumption.

Interventions

  • DRUG Placebo
  • DRUG Gabapentin

Study Locations (1)

Missouri

  • Washington University School of Medicine - St Louis

Trial Details

FieldValue
Enrollment Target 123 participants
Start Date 2016-06-24
Est. Completion 2017-06-21
Phase Phase 4

What the finished NCT02926573 record still lists

NCT02926573 is an interventional study that assigns participants to a tested intervention. The registered 123 participants enrollment target is mid-sized for trials with a published cap, below the 260-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (53% lower).

The record links to 3 conditions, with Head and Neck Cancer appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT02926573 reports a single indexed study location in Missouri.

Frequently Asked Questions

What is clinical trial NCT02926573 about?

NCT02926573 is a clinical study titled "Perioperative Gabapentin Use In Head And Neck Mucosal Surgery Patients". Patient satisfaction with healthcare is increasingly being utilized as a metric to reflect provider and hospital quality of care. Furthermore, at the core of a healthcare team and healthcare system is the desire to provide patients with the best possible care in order to achieve the best possible ou...

What is the current status of trial NCT02926573?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 123 participants. The study started on 2016-06-24. Estimated completion is 2017-06-21.

What conditions does trial NCT02926573 study?

This clinical trial studies the following conditions: Head and Neck Cancer, Postoperative Pain, Acute Pain.

What interventions are being tested in trial NCT02926573?

The interventions under investigation include: Placebo (DRUG), Gabapentin (DRUG).

Who is sponsoring clinical trial NCT02926573?

This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02926573 being conducted?

This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Head and Neck Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02926573's enrollment target sits among peer trials

123 71st of 250 higher than 180 of 250 other Head and Neck Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Head and Neck Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05285891 · 123 participants · Phase 4

    Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis

  • NCT05334368 · 123 participants · Phase 3

    Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial

  • NCT06088355 · 123 participants · NA

    Moderate Versus High Volume Light-Moderate Intensity Exercise for People With Moderate Parkinson's Disease

  • NCT06111131 · 123 participants · NA

    Ancora-SB Overtube Complete Positioning and Optical Visualization During Endoscopic Procedures

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02926573, the US trial registry maintained by the National Library of Medicine. NCT02926573 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.